Concepts (199)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bone Neoplasms | 20 | 2020 | 2668 | 2.820 |
Why?
|
| Magnetic Resonance Imaging | 19 | 2024 | 7921 | 1.730 |
Why?
|
| Contrast Media | 7 | 2024 | 1510 | 1.670 |
Why?
|
| Computed Tomography Angiography | 4 | 2019 | 247 | 1.630 |
Why?
|
| Soft Tissue Neoplasms | 4 | 2020 | 920 | 1.520 |
Why?
|
| Fluorodeoxyglucose F18 | 8 | 2015 | 1259 | 1.240 |
Why?
|
| Image Enhancement | 5 | 2019 | 555 | 1.200 |
Why?
|
| Gadolinium | 3 | 2020 | 171 | 1.140 |
Why?
|
| Whole Body Imaging | 4 | 2020 | 113 | 1.020 |
Why?
|
| Tomography, X-Ray Computed | 19 | 2020 | 7782 | 1.000 |
Why?
|
| Radiopharmaceuticals | 8 | 2020 | 1338 | 0.960 |
Why?
|
| Free Tissue Flaps | 2 | 2019 | 373 | 0.910 |
Why?
|
| Positron-Emission Tomography | 11 | 2015 | 2198 | 0.900 |
Why?
|
| Osteosarcoma | 4 | 2017 | 948 | 0.860 |
Why?
|
| Positron Emission Tomography Computed Tomography | 2 | 2020 | 878 | 0.850 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 3 | 2020 | 341 | 0.840 |
Why?
|
| Musculoskeletal Diseases | 3 | 2023 | 96 | 0.830 |
Why?
|
| Sarcoma | 2 | 2024 | 1840 | 0.780 |
Why?
|
| Image Interpretation, Computer-Assisted | 4 | 2013 | 593 | 0.720 |
Why?
|
| Nephrogenic Fibrosing Dermopathy | 1 | 2019 | 9 | 0.700 |
Why?
|
| Scapula | 1 | 2019 | 33 | 0.660 |
Why?
|
| Bone Transplantation | 1 | 2019 | 147 | 0.620 |
Why?
|
| Fibula | 1 | 2018 | 152 | 0.560 |
Why?
|
| Thigh | 2 | 2016 | 164 | 0.530 |
Why?
|
| Radiography | 11 | 2023 | 1988 | 0.520 |
Why?
|
| Multimodal Imaging | 3 | 2014 | 551 | 0.500 |
Why?
|
| Fracture Fixation, Internal | 2 | 2008 | 94 | 0.500 |
Why?
|
| Sarcoma, Ewing | 2 | 2017 | 426 | 0.480 |
Why?
|
| Pattern Recognition, Automated | 1 | 2014 | 125 | 0.450 |
Why?
|
| Radiography, Thoracic | 2 | 2012 | 473 | 0.430 |
Why?
|
| Tomography, Emission-Computed | 2 | 2012 | 335 | 0.410 |
Why?
|
| Preoperative Care | 2 | 2019 | 1547 | 0.390 |
Why?
|
| Bony Callus | 2 | 2008 | 6 | 0.380 |
Why?
|
| Fracture Healing | 2 | 2008 | 42 | 0.370 |
Why?
|
| Spinal Diseases | 1 | 2011 | 131 | 0.360 |
Why?
|
| Surgical Flaps | 1 | 2016 | 881 | 0.360 |
Why?
|
| Pacemaker, Artificial | 1 | 2012 | 202 | 0.350 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 2 | 2020 | 165 | 0.350 |
Why?
|
| Defibrillators, Implantable | 1 | 2012 | 226 | 0.340 |
Why?
|
| Humans | 51 | 2024 | 270757 | 0.340 |
Why?
|
| Hyperostosis | 1 | 2009 | 6 | 0.330 |
Why?
|
| Osteitis | 1 | 2009 | 16 | 0.330 |
Why?
|
| Ilizarov Technique | 1 | 2008 | 3 | 0.330 |
Why?
|
| Breast Neoplasms | 9 | 2016 | 16186 | 0.320 |
Why?
|
| Bone Diseases | 1 | 2009 | 143 | 0.300 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2020 | 10349 | 0.300 |
Why?
|
| Femoral Neoplasms | 2 | 2013 | 65 | 0.290 |
Why?
|
| Fractures, Ununited | 2 | 2008 | 14 | 0.280 |
Why?
|
| Osteopetrosis | 1 | 2006 | 26 | 0.270 |
Why?
|
| Median Neuropathy | 1 | 2006 | 4 | 0.270 |
Why?
|
| Sensitivity and Specificity | 6 | 2013 | 5184 | 0.270 |
Why?
|
| Lipomatosis | 1 | 2006 | 22 | 0.260 |
Why?
|
| Fractures, Bone | 1 | 2008 | 312 | 0.260 |
Why?
|
| Hamartoma | 1 | 2006 | 87 | 0.250 |
Why?
|
| Fingers | 1 | 2006 | 129 | 0.250 |
Why?
|
| Muscle Weakness | 1 | 2006 | 112 | 0.250 |
Why?
|
| Algorithms | 3 | 2013 | 3906 | 0.240 |
Why?
|
| Tibial Fractures | 2 | 2002 | 63 | 0.240 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2024 | 1708 | 0.230 |
Why?
|
| Giant Cell Tumor of Bone | 1 | 2003 | 53 | 0.220 |
Why?
|
| Adult | 21 | 2024 | 81523 | 0.210 |
Why?
|
| Neoplasm Metastasis | 3 | 2011 | 5324 | 0.210 |
Why?
|
| Middle Aged | 19 | 2024 | 90004 | 0.200 |
Why?
|
| Radionuclide Imaging | 3 | 2011 | 658 | 0.200 |
Why?
|
| Female | 26 | 2024 | 148398 | 0.190 |
Why?
|
| Subclavian Artery | 1 | 2001 | 79 | 0.190 |
Why?
|
| Thoracic Outlet Syndrome | 1 | 2001 | 25 | 0.190 |
Why?
|
| Aged | 15 | 2024 | 73156 | 0.190 |
Why?
|
| Radius | 1 | 2000 | 44 | 0.180 |
Why?
|
| Retrospective Studies | 11 | 2024 | 39670 | 0.180 |
Why?
|
| Male | 19 | 2024 | 128346 | 0.180 |
Why?
|
| Bone and Bones | 2 | 2017 | 612 | 0.180 |
Why?
|
| Lumbosacral Region | 1 | 2019 | 55 | 0.170 |
Why?
|
| Risk Assessment | 4 | 2019 | 6829 | 0.160 |
Why?
|
| Diagnostic Imaging | 2 | 2020 | 1178 | 0.160 |
Why?
|
| Wilms Tumor | 1 | 2001 | 297 | 0.160 |
Why?
|
| Radiology | 1 | 2023 | 428 | 0.150 |
Why?
|
| Perforator Flap | 1 | 2019 | 96 | 0.150 |
Why?
|
| Reproducibility of Results | 4 | 2013 | 6169 | 0.150 |
Why?
|
| Neoplasm Staging | 9 | 2015 | 13976 | 0.150 |
Why?
|
| Plasmablastic Lymphoma | 1 | 2015 | 38 | 0.130 |
Why?
|
| Thrombocytopenia | 1 | 2000 | 871 | 0.130 |
Why?
|
| Neoplasm Invasiveness | 1 | 2003 | 4067 | 0.120 |
Why?
|
| Aged, 80 and over | 6 | 2024 | 30941 | 0.120 |
Why?
|
| Prevalence | 3 | 2011 | 3416 | 0.120 |
Why?
|
| Bone Density Conservation Agents | 1 | 2016 | 205 | 0.120 |
Why?
|
| Diphosphonates | 1 | 2016 | 264 | 0.120 |
Why?
|
| Pain | 1 | 2002 | 1695 | 0.110 |
Why?
|
| Postoperative Complications | 1 | 2008 | 5679 | 0.110 |
Why?
|
| Bone Cysts, Aneurysmal | 1 | 2013 | 20 | 0.110 |
Why?
|
| Biopsy | 1 | 2020 | 3544 | 0.100 |
Why?
|
| Adolescent | 6 | 2014 | 32515 | 0.100 |
Why?
|
| Dasatinib | 1 | 2016 | 881 | 0.100 |
Why?
|
| Tibia | 1 | 2013 | 127 | 0.100 |
Why?
|
| Treatment Outcome | 6 | 2024 | 33785 | 0.100 |
Why?
|
| Syndrome | 2 | 2009 | 1400 | 0.100 |
Why?
|
| Equipment Failure | 1 | 2012 | 198 | 0.100 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2016 | 16593 | 0.100 |
Why?
|
| Azygos Vein | 1 | 2011 | 18 | 0.100 |
Why?
|
| Mediastinal Neoplasms | 1 | 2015 | 429 | 0.090 |
Why?
|
| Gadolinium DTPA | 1 | 2011 | 173 | 0.090 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 3 | 2015 | 6982 | 0.090 |
Why?
|
| Muscle Neoplasms | 1 | 2011 | 108 | 0.090 |
Why?
|
| Patient Positioning | 1 | 2012 | 195 | 0.090 |
Why?
|
| Vena Cava, Superior | 1 | 2011 | 78 | 0.090 |
Why?
|
| Observer Variation | 1 | 2013 | 721 | 0.090 |
Why?
|
| Young Adult | 5 | 2015 | 22044 | 0.090 |
Why?
|
| Thoracic Vertebrae | 1 | 2011 | 201 | 0.090 |
Why?
|
| Chronic Disease | 2 | 2009 | 1849 | 0.090 |
Why?
|
| Lumbar Vertebrae | 1 | 2011 | 249 | 0.090 |
Why?
|
| Reference Standards | 1 | 2011 | 368 | 0.090 |
Why?
|
| Imidazoles | 1 | 2016 | 1059 | 0.090 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2019 | 916 | 0.090 |
Why?
|
| Sciatic Nerve | 1 | 2010 | 123 | 0.090 |
Why?
|
| Carcinoma | 2 | 2011 | 2627 | 0.080 |
Why?
|
| Acne Vulgaris | 1 | 2009 | 43 | 0.080 |
Why?
|
| Periosteum | 1 | 2009 | 41 | 0.080 |
Why?
|
| Ribs | 1 | 2009 | 85 | 0.080 |
Why?
|
| Radiotherapy | 1 | 2015 | 1858 | 0.080 |
Why?
|
| World Health Organization | 1 | 2010 | 329 | 0.080 |
Why?
|
| Catheterization, Central Venous | 1 | 2011 | 365 | 0.080 |
Why?
|
| Nerve Block | 1 | 2010 | 185 | 0.080 |
Why?
|
| Necrosis | 1 | 2009 | 603 | 0.070 |
Why?
|
| Kidney Neoplasms | 1 | 2001 | 3142 | 0.070 |
Why?
|
| Patient Safety | 1 | 2012 | 651 | 0.070 |
Why?
|
| Child | 5 | 2014 | 30328 | 0.070 |
Why?
|
| Subtraction Technique | 1 | 2007 | 145 | 0.070 |
Why?
|
| Feasibility Studies | 1 | 2011 | 2345 | 0.070 |
Why?
|
| Osteomyelitis | 1 | 2008 | 257 | 0.060 |
Why?
|
| Lower Extremity | 2 | 2010 | 284 | 0.060 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2015 | 1734 | 0.060 |
Why?
|
| Follow-Up Studies | 4 | 2012 | 15237 | 0.060 |
Why?
|
| Wound Healing | 1 | 2009 | 750 | 0.060 |
Why?
|
| Prognosis | 5 | 2012 | 22452 | 0.060 |
Why?
|
| Infant | 3 | 2009 | 13854 | 0.060 |
Why?
|
| Disease-Free Survival | 3 | 2011 | 10249 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2010 | 5102 | 0.050 |
Why?
|
| Orthopedic Procedures | 1 | 2003 | 143 | 0.050 |
Why?
|
| Survival Rate | 3 | 2012 | 12516 | 0.050 |
Why?
|
| Nerve Compression Syndromes | 1 | 2001 | 32 | 0.050 |
Why?
|
| Benchmarking | 1 | 2024 | 284 | 0.050 |
Why?
|
| Spine | 1 | 2023 | 311 | 0.050 |
Why?
|
| Bone Screws | 1 | 2002 | 86 | 0.050 |
Why?
|
| Pseudarthrosis | 1 | 2001 | 7 | 0.050 |
Why?
|
| Risk Factors | 3 | 2011 | 17819 | 0.050 |
Why?
|
| Survival Analysis | 2 | 2010 | 9304 | 0.050 |
Why?
|
| Combined Modality Therapy | 4 | 2015 | 9040 | 0.050 |
Why?
|
| Genes, Wilms Tumor | 1 | 2001 | 62 | 0.050 |
Why?
|
| Bone Diseases, Developmental | 1 | 2001 | 70 | 0.050 |
Why?
|
| Child, Preschool | 3 | 2009 | 16907 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2012 | 13343 | 0.040 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2002 | 223 | 0.040 |
Why?
|
| Neurofibromatosis 1 | 1 | 2001 | 151 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2009 | 4881 | 0.040 |
Why?
|
| Texas | 1 | 2009 | 6412 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2009 | 4385 | 0.040 |
Why?
|
| Doxorubicin | 2 | 2015 | 3138 | 0.040 |
Why?
|
| Arteries | 1 | 2019 | 294 | 0.040 |
Why?
|
| Disease Progression | 1 | 2009 | 6891 | 0.040 |
Why?
|
| Neoplasms | 1 | 2024 | 15849 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2024 | 2286 | 0.030 |
Why?
|
| Hemorrhage | 1 | 2000 | 742 | 0.030 |
Why?
|
| Neoadjuvant Therapy | 1 | 2009 | 5188 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2001 | 1934 | 0.030 |
Why?
|
| src-Family Kinases | 1 | 2016 | 487 | 0.030 |
Why?
|
| Etoposide | 1 | 2015 | 905 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2015 | 880 | 0.030 |
Why?
|
| Prednisone | 1 | 2015 | 1039 | 0.030 |
Why?
|
| Time Factors | 1 | 2006 | 13102 | 0.020 |
Why?
|
| Ireland | 1 | 2011 | 31 | 0.020 |
Why?
|
| Vincristine | 1 | 2015 | 1572 | 0.020 |
Why?
|
| Transplantation, Autologous | 1 | 2015 | 2049 | 0.020 |
Why?
|
| Dexamethasone | 1 | 2015 | 1506 | 0.020 |
Why?
|
| Radiology Information Systems | 1 | 2011 | 118 | 0.020 |
Why?
|
| Rituximab | 1 | 2015 | 1589 | 0.020 |
Why?
|
| Sample Size | 1 | 2010 | 206 | 0.020 |
Why?
|
| Femur | 1 | 2010 | 162 | 0.020 |
Why?
|
| Breast | 1 | 2016 | 1364 | 0.020 |
Why?
|
| Body Height | 1 | 2010 | 232 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 2011 | 11761 | 0.020 |
Why?
|
| Rare Diseases | 1 | 2011 | 360 | 0.020 |
Why?
|
| Sheep | 1 | 2009 | 276 | 0.020 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2009 | 209 | 0.020 |
Why?
|
| Neoplasm Grading | 1 | 2012 | 1820 | 0.020 |
Why?
|
| ROC Curve | 1 | 2011 | 1221 | 0.020 |
Why?
|
| Cyclophosphamide | 1 | 2015 | 3231 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2000 | 8566 | 0.020 |
Why?
|
| Linear Models | 1 | 2010 | 1092 | 0.020 |
Why?
|
| Salvage Therapy | 1 | 2015 | 2117 | 0.020 |
Why?
|
| Receptor, ErbB-2 | 1 | 2016 | 2648 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2012 | 2848 | 0.020 |
Why?
|
| Inflammatory Breast Neoplasms | 1 | 2011 | 528 | 0.020 |
Why?
|
| Comorbidity | 1 | 2011 | 2430 | 0.020 |
Why?
|
| Skin | 1 | 2010 | 1280 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2011 | 4330 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 2009 | 3033 | 0.010 |
Why?
|
| Lymphatic Metastasis | 1 | 2009 | 4967 | 0.010 |
Why?
|
| United States | 1 | 2011 | 15978 | 0.010 |
Why?
|
| Animals | 1 | 2009 | 62754 | 0.000 |
Why?
|